CompletedNot Applicable

Real World Data Analysis: Impact of High-Frequency REN Treatments As Migraine Preventive Therapy in Adolescence

United States83 participantsStarted 2023-04-01

Plain-language summary

This is a post-marketing study investigating the safety and efficacy of the REN device (Nerivio by Theranica, ISRAEL) in adolescents with migraine. The data analysis will test the ability of Frequent use of REN for the acute treatment of migraine to reduce the number of monthly migraine days in subsequent months, suggesting potential preventive benefits.

Who can participate

Age range12 Years – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * patient age is 12 Years to 18 Years * Patient is using the Nerivio device for acute treatment of migraine * Patient treated at least 10 treatments in his first month of using Nerivio and at least 3 treatments in each of the two consecutive months (months 2 and 3 Exclusion Criteria: * Treatments shorter than 30 minutes

What they're measuring

Reduction in Mean Monthly Migraine Treatment Days

Timeframe: 3 months

Trial details

NCT IDNCT05769322

SponsorTheranica

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2023-04-15

View on ClinicalTrials.gov More Migraine trials